Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients

NCT ID: NCT05170893 Phase: NA Status: COMPLETED Enrollment: 36 Completion: 2022-07-26

Conditions

Hemodialysis

Interventions

Coenzyme Q10, Placebo

Summary

All chronic kidney disease patients, whether on regular hemodialysis or not, are at high risk of cardiovascular diseases. This is mainly due to increased oxidative stress, reduced antioxidants and generalized inflammation. Coenzyme Q10 is a vitamin-like antioxidant synthesized in almost all body cells, and it is also available in many dietary sources. It was observed that chronic kidney disease patients have low plasma levels of Coenzyme Q10. Clinical benefits of Coenzyme Q10 supplementation have been documented for various cardiovascular and neurodegenerative disorders. The investigators believe that Coenzyme Q10 supplementation may have potential benefits in pediatric patients receiving hemodialysis; mainly due to its antioxidant activity and anti-inflammatory effects.

Primary Outcome

Change in Malondialdehyde (MDA)

Source

ClinicalTrials.gov